Search Results
Your search for ,led matches 5950 pages
Showing 5101 - 5150ASCO Celebrates Oncology Luminaries for 50th Anniversary
In the 50 years since the American Society of Clinical Oncology was founded, the treatment of cancer has advanced dramatically, due to the work of researchers making important scientific breakthroughs, physicians responsible for delivering those advances to patients, and countless others who...
The Evolving Role of Surgery in Germ Cell Tumors
Over the past several decades, the role of postchemotherapy surgery for advanced testicular cancer has evolved with regard to patient selection, surgical planning, lymph node dissection, and surgical technique. To add clarity to this complex clinical setting, The ASCO Post recently spoke with...
PREVAIL Trial: Enzalutamide Before Chemotherapy Prolongs Survival in Metastatic Prostate Cancer
The androgen-receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England Journal of Medicine, Tomasz M. Beer, MD, of...
EGFR as a Therapeutic Target for Gastroesophageal Cancer—or Is It Really?
The epidermal growth factor receptor (EGFR) gene is often amplified and its protein overexpressed in upper gastrointestinal cancers—and overexpression has prognostic value. With the advent of monoclonal antibodies and tyrosine kinase inhibitors against EGFR, we have witnessed a rash of randomized...
NEPA for Chemotherapy-Induced Nausea and Vomiting: Key Endpoints and Additional Analyses Show Strong Efficacy
For the prevention of chemotherapy-induced nausea and vomiting, NEPA, a novel combination of a neurokinin-1 (NK1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), has been studied in three pivotal trials that were recently published in the Annals of Oncology.1-3 Further...
90 Countries Participate in the 5th World Congress of the International Federation of Head and Neck Oncologic Societies in New York
A spectacular parade of nations from 90 countries led by the Emerald Society Pipes and Drums from the New York City Police Department opened the 5th World Congress of the International Federation of Head and Neck Oncologic Societies (IFHNOS) on July 27 in New York City. The 4-day event was held in...
Who Will Care for Patients With Cancer?
The workforce numbers show a disturbing trend. According to a recent study by ASCO, by 2025, overall demand for oncology services is projected to grow by 40%, but physician supply is predicted to increase by only 25%, generating a shortage of 2,258 oncologists providing full-time equivalent...
Recent FDA Drug Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare B-Cell Lymphomas
Recent approvals announced by the U.S. Food and Drug Administration (FDA) have led to increased treatment options for managing several difficult-to-treat hematologic B-cell cancers. The newly approved drugs and/or their indications include the oral PI3K delta inhibitor idelalisib (Zydelig) for the...
Pioneer in Fight Against Tobacco, Emanuel Farber, MD, PhD, Dies at 85
On December 11, 1969, a soft-spoken pathologist wearing outsized spectacles answered a long and complex series of questions by the legal team representing Liggett & Myers Tobacco Company, the maker of Chesterfield cigarettes. The tobacco lawyers contended that one Leslie Thayer—a lifelong...
Jesse L. Steinfeld, MD, Past Surgeon General, ASCO President, Dies at 87
The 1964 Surgeon General’s Report on Smoking and Health started a culture change in the way Americans viewed tobacco and their health, and has saved countless million of lives. But the 1964 Report remained scientifically ambiguous on certain vital issues, such as the effect smoking had on the...
First Prospective Study of Rare Lymphoma Shows Promising but Inconclusive Results With DA-EPOCH-R
Presenting “the first prospective study” of mediastinal gray zone lymphoma, researchers from the National Cancer Institute reported that DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan) and filgrastim (Neupogen)...
Royal Society Presents 2014 Royal Medal to Tony Hunter, PhD, FRS, Salk Professor
Tony Hunter, PhD, FRS, has been awarded the 2014 Royal Medal for Biological Sciences by the Royal Society, an international fellowship of scientists based in the United Kingdom. The award recognizes Dr. Hunter, Director of Salk Institute Cancer Center in San Diego, for his contributions to the...
Gynecologic Cancer Care: Collaboration With Resource-Challenged Ethiopia
Over the past 40 years, largely because of universal Pap screening, cervical cancer deaths have been drastically reduced in the United States and other wealthy industrialized countries. However, cervical cancer is still a leading cause of cancer death among women in resource-challenged areas of the ...
How Pharmaceutical Companies Are Partnering With Patient Advocates to Ensure Access to Oncology Care
Thomas P. Sellers, MPA, has been a tireless advocate for patients’ rights for more than 20 years. A 15-year prostate cancer survivor and only child, Mr. Sellers said it was his mother’s death from lung cancer when she was 51, followed by the death of his father from glioblastoma multiforme that led ...
ASTRO Awards $35,500 in Individual Grants to 43 Researchers
The American Society for Radiation Oncology (ASTRO) has selected 43 recipients to receive a total of $35,500 for the 2014 Annual Meeting Abstract Awards. The awardees will be recognized at ASTRO’s 56th Annual Meeting. ASTRO’s 56th Annual Meeting, takes place San Francisco’s Moscone Center,...
Phase III Trial of Figitumumab Plus Chemotherapy in Advanced NSCLC Stopped Early for Futility and Increased Harm
In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal antibody...
#WeConquerCancer: Creative Fundraisers From Committed Conquerors
Conquer Cancer Foundation donors are a consistently creative bunch when it comes to encouraging others to help conquer cancer: Tyler invited his friends and family to a charity spin class; elementary school students in Malibu, California, sold bracelets in honor of their principal; Steve competed...
Advances in Hematopoietic Cell Transplant for Pediatric AML Reduce Toxicity and Expand Access, but Relapse Remains a Problem
Advances in allogeneic hematopoietic cell transplantation for children with acute myeloid leukemia (AML) have resulted in less toxic pretransplant conditioning regimens and expanded access to transplantation, but post-treatment leukemic relapse remains a big problem. The progress and continuing...
Bortezomib Retreatment in Multiple Myeloma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 8, 2014, the approved use of bortezomib (Velcade) in...
Charles LeMaistre, MD, and Hans Mark, PhD, Named Chancellors Emeritus by the University of Texas System Board of Regents
Two former Chancellors, Charles LeMaistre, MD, and Hans Mark, PhD, were recently given the honorific title Chancellors Emeritus by the University of Texas System Board of Regents. “Charles LeMaistre and Hans Mark were visionary chancellors who expanded the UT System into new directions that...
Emerging Approaches in Acute Myeloid Leukemia
With the emergence of molecular diagnostics and new therapeutics, the treatment of acute myeloid leukemia (AML) is entering a new era. Hugo F. Fernandez, MD, Associate Chief of Blood and Marrow Transplantation at Moffitt Cancer Center in Tampa, Florida, spoke with The ASCO Post about how he...
Targeting KRAS Mutations in Lung Cancer: No Longer Impossible
The KRAS mutation has long been considered “undruggable,” but new approaches in drug development may change this. The end result could be effective new treatment options for KRAS-mutated non–small cell lung cancer (NSCLC), according to David R. Gandara, MD, who described the emerging findings at...
Study Estimates Risk of Premature Menopause After Treatment for Hodgkin Lymphoma
Previous research has suggested that women with Hodgkin lymphoma who receive certain types of chemotherapy or radiotherapy are at increased risk of future infertility, but there was insufficient information to provide patients with detailed advice. In a study published in the Journal of the...
Jury Still Out on Interim PET for Response-Adapted Therapy in Hodgkin Lymphoma
Interim positron-emission tomography (PET) scans provide good prognostic information in patients with Hodgkin lymphoma, but more research is needed to determine whether patients benefit when the findings are used to alter treatment, according to Oliver Press, MD, PhD, Professor at the University of ...
Oncology Practice: What Are the Factors Driving Change?
Clinical practice changes in response to new medical evidence, but not always immediately or all at once. So what else determines whether and how quickly practice changes in response to evidence, for instance, that a widely used drug is effective only in patients with a certain biomarker? In a new...
My Priorities for the Year Ahead
I am honored and privileged to lead ASCO during its 51st year, a year that promises to bring both challenges and opportunities to our members and our patients. As the theme for my Presidential term, I’ve chosen Illumination and Innovation: Transforming Data Into Learning, because we are positioned...
Allogeneic Conditioning Regimen Reduces Myelosuppression, Graft-vs-Host Disease in Lymphocytic Leukemia/Lymphoma
The combination of bendamustine (Treanda), fludarabine, and rituximab (Rituxan), or BFR, was shown to be safe and effective conditioning for patients with relapsed chronic lymphocytic leukemia/lymphoma receiving allogeneic stem cell transplantation from related or unrelated donors. “Remarkably,...
Breast Cancer Has Led Me to Careers in Activism and Filmmaking
The last thing I expected to find when I returned home after a summer vacation celebrating my 50th birthday was a letter from my gynecologist saying the routine mammogram I had before I left found suspicious-looking calcifications in my right breast and that I should see a surgeon right away. Being ...
UNC Lineberger Secures Three Major NCI Grants to Advance the Nation’s Clinical Trials Program
At the national level, clinical trials are seeing a lot of change. In an effort to increase efficiency and keep up with national changes in the types of clinical trials offered to cancer patients, the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN) is undergoing a major...
Immunotherapy Research of James P. Allison, PhD, Has Led to a Paradigm Shift in the Treatment of Cancer
James P. Allison, PhD, has been bucking the status quo since he was a teenager growing up in the small agricultural town of Alice, Texas, in the 1950s and 1960s. He first butted heads with authority figures when he was in high school and learned that his biology class had omitted the teaching of...
Breast Cancer Screening Using Tomosynthesis in Combination With Digital Mammography
In a study reported in JAMA and reviewed in this issue of The ASCO Post, Friedewald and colleagues1 showed that the addition of tomosynthesis to digital mammography2 resulted in a decrease in the screening recall rate3 and an increase in the cancer detection rate.4,5 This retrospective analysis of...
NIH Launches Human Safety Study of Ebola Vaccine Candidate
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched initial human testing of an investigational vaccine to prevent Ebola virus disease, according to a news release issued by NIH. The early-stage trial has begun initial human...
ASCO University’s New Cancer Genetics Program
Over the past decade, ASCO has launched multiple initiatives on cancer genetics that complement the rapid progress in the field. These initiatives have resulted in educational offerings and policy recommendations that have improved both preventive and therapeutic options for patients with cancer...
Lung Cancer Webinar Highlights Brain Metastases and Thoracic Radiotherapy
Postoperative radiation therapy, given after adjuvant chemotherapy, significantly increased overall survival in non–small cell lung cancer (NSCLC) compared to chemotherapy alone, according to a study reported at ASCO’s 2014 Annual Meeting.1 That study, an analysis of records in the National Cancer...
Adding Antiangiopoietin Agent Trebananib to Paclitaxel Improves Progression-Free Survival in Recurrent Epithelial Ovarian Cancer
Trebananib inhibits angiogenesis by blocking the binding of angiopoietins 1 and 2 to the Tie2 receptor expressed on endothelial cells, a mechanism that differs from vascular endothelial growth factor (VEGF) inhibitors and that involves a different signaling pathway. In the phase III TRINOVA-1 trial ...
Studies Help Refine Management of Prostate Cancer
Several studies reported at this year’s ASCO Annual Meeting address gray areas in the management of prostate cancer, according to Evan Y. Yu, MD, Associate Professor at the University of Washington and the Seattle Cancer Care Alliance. “In prostate cancer, probably the most excitement has happened...
Hsp90 Inhibitors May Soon Transition Into Clinic
Inhibitors of heat shock protein 90 (Hsp90) look promising for the treatment of advanced non–small cell lung cancer (NSCLC) and have the advantage of not needing a specific mutation to target, said Suresh S. Ramalingam, MD, Professor and Chief of Medical Oncology at the Winship Cancer Institute of...
In Advanced Lung Cancer, Targeted Combinations Are Still Works in Progress
For the treatment of advanced non–small cell lung cancer (NSCLC), combinations of targeted agents are of great research interest but have not yet been shown to improve outcomes. Single-agent treatment with tyrosine kinase inhibitors, therefore, remains the standard of care for patients with...
AACR 2014 Cancer Progress Report Call to Action: Prioritize Federal Funding for Biomedical Research
Last month, the American Association for Cancer Research (AACR) released its 2014 Cancer Progress Report: Transforming Lives Through Research, which highlights the quickening pace of drug development and approval, especially in molecularly targeted agents, that are leading to increased numbers of...
Patients With DCIS Have Decreased Risk of Cardiovascular Death, Independent of Treatment
Recent concerns about potential overdiagnosis and overtreatment of ductal carcinoma in situ of the breast (DCIS) led researchers in the Netherlands to study late effects of treatment, such as cardiovascular disease, morbidity, and mortality in a large population-based cohort of DCIS patients....
Moderate Form of Male Pattern Baldness Associated With Increased Risk of Aggressive Prostate Cancer
Men with moderate pattern baldness on the front and the crown of the head at age 45 had a 40% increased risk, compared to men with no baldness at that age, of developing prostate cancer later in life, according to a study led by researchers from the National Cancer Institute (NCI) and published in...
Fear
The following essay by Michael Feinstein, MD, is excerpted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was co-edited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org....
Ketan K. Badani, MD, Additional Staff, Appointed to Mount Sinai Health System
Ketan K. Badani, MD, Professor of Urology, Icahn School of Medicine at Mount Sinai in New York, has been named Vice Chairman of Urology and Robotic Operations and Director of the Comprehensive Kidney Cancer Program for the Mount Sinai Health System. Dr. Badani will also serve as Director of Robotic ...
James Herman, MD, Named Co-Leader of UPCI Lung Cancer Program
A leader in the field of epigenetics whose work has led to important discoveries into how cancer develops and progresses has been named the co-leader of the Lung Cancer Program at the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter. James Herman, MD, comes to...
Genetic ‘Hotspot’ Linked to Endometrial Cancer Aggressiveness
Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone, and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same....
Now in Its 71st Year, CancerCare Looks to Expand Services to Patients and Caregivers
Eleven days before Patricia J. Goldsmith, joined CancerCare as its CEO last May, she received the unexpected news that she had early-stage colorectal cancer. While the diagnosis was shocking, Ms. Goldsmith said it gave her a unique perspective on what it means to have this serious disease and a...
Treating Sarcomas in 2014
In 2014, about 15,000 people in the United States will be diagnosed with some form of sarcoma, and of those, approximately 5,000 adults and children are expected to die of the disease. Sarcomas are a heterogeneous group of mesenchymal malignancies that have historically been difficult to diagnose...
Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 10, 2014, the androgen receptor inhibitor...
Early Study Reports Modified Vitamin D Has Potential in Treatment for Pancreatic Cancer
Researchers at the Salk Institute have reported on a synthetic derivative of vitamin D able to collapse the barrier of cells shielding pancreatic tumors, making this challenging cancer more susceptible to therapeutic drugs. The discovery has led to human trials for pancreatic cancer, even in...
Despite Growing Awareness, the Global Crisis of Untreated Cancer Pain Persists
Each day, millions of patients with cancer around the world suffer unrelieved pain because they are denied morphine, the gold standard of cancer pain control. The World Health Organization has called access to morphine a human rights issue. Not surprisingly, the crisis in unrelieved cancer pain is...
